Institutional Review Board, Hospital for Special Surgery
March 28, 2014
The safety of study participants is our top priority. The trial is approved and periodically reviewed by an Institutional Review Board (IRB), which includes doctors, administrators, ethicists, and members of the general public. The safety of clinical trials is reviewed by the U.S. Food and Drug Administration.
Before enrolling in a clinical trial, the investigator will explain the purpose of the trial, its expected benefits, any possible risks or side effects, and what your role will be. This is the time to ask questions! If you want to join the trial, you must sign the informed consent documents. You can leave a clinical trial at any time without penalty.
For further information, see Understanding Clinical Trials.
Jessica K. Gordon, MD
Lindsay Lally, MD
This prospective observational study will evaluate the long-term safety of MabThera/Rituxan (rituximab) in patients with granulomatosis with polyangiitis (Wegener's) or microscopic polyangiitis. Data will be collected for a maximum of 4 years from patients initiated on MabThera/Rituxan therapy by their physician according to prescribing information. Recruitment is closed.
• Adult patients, >/= 18 years of age
• Granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), according to Chapel Hill Consensus Conference Definitions for MPA and ACR Criteria for the Classification of GPA
• Disease severity requiring rituximab treatment per the investigator's assessment
• Prior use of rituximab (except if received within 4 weeks of screening)
• Known hypersensitivity to rituximab, to any component of the product, or to murine proteins
• Pregnant or breastfeeding women
• Diagnosis of Churg-Strauss syndrome